Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Accumulated Expenses: 2016-2025

Historic Accumulated Expenses for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Sep 2025 value amounting to $84.5 million.

  • Rhythm Pharmaceuticals' Accumulated Expenses rose 54.13% to $84.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.5 million, marking a year-over-year increase of 54.13%. This contributed to the annual value of $62.7 million for FY2024, which is 29.83% up from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Accumulated Expenses of $84.5 million as of Q3 2025, which was up 22.07% from $69.2 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Accumulated Expenses registered a high of $84.5 million during Q3 2025, and its lowest value of $7.2 million during Q1 2021.
  • Over the past 3 years, Rhythm Pharmaceuticals' median Accumulated Expenses value was $48.3 million (recorded in 2023), while the average stood at $52.9 million.
  • In the last 5 years, Rhythm Pharmaceuticals' Accumulated Expenses plummeted by 36.60% in 2021 and then skyrocketed by 252.43% in 2022.
  • Over the past 5 years, Rhythm Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $30.1 million in 2021, then climbed by 9.34% to $32.9 million in 2022, then soared by 46.72% to $48.3 million in 2023, then climbed by 29.83% to $62.7 million in 2024, then surged by 54.13% to $84.5 million in 2025.
  • Its last three reported values are $84.5 million in Q3 2025, $69.2 million for Q2 2025, and $59.3 million during Q1 2025.